UnitedHealth revealed in its first-quarter earnings report of 2025 that it faced a $9.8 billion year-over-year increase in revenues so far this year and managed to serve 780,000 new customers. However, UnitedHealth CEO Andrew Witty warned that the company did not meet expectations.
When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have major ramifications for the Medicare drug price negotiation program, a signature accomplishment of former President Biden that President Trump has also embraced.
At least half a dozen states are weighing new restrictions aimed at limiting pharmacy benefit managers' ability to influence drug prices, including prohibitions on steering business to affiliated pharmacies. With Congress gridlocked on PBM legislation, more states are taking the lead in addressing industry practices that critics say drive up costs and are pushing independent pharmacies out of business.
The Supreme Court today is set to hear arguments in a case challenging a provision of the Affordable Care Act that requires private insurers to cover health care screenings, tests and checkups for free. Experts say the court's ruling in the case, called Kennedy v. Braidwood Management, could have sweeping consequences for patient access to preventive healthcare across the United States.
Improved birth rates are a stated priority for President Donald Trump's administration—but proposed budget cuts could make it harder for many Americans to afford a safe, healthy pregnancy.
UnitedHealth Group surprised investors with what its CEO said was an 'unusual and unacceptable' quarterly earnings miss, and it lowered its outlook for the full year due to higher-than-expected medical costs, sparking a more than 20% selloff in shares that reverberated across the sector. The company's first earnings miss since 2008 and accompanying bleak forecast sent investors to the exits, as they were hoping the U.S. insurer would maintain its profit outlook on expectations that demand for medical services would be similar to 2024.